We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HAG:XETRHENSOLDT AG Analysis

Data as of 2026-05-25 - not real-time

$10.31

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Hensoldt AG is currently priced well above its intrinsic valuation, with market pricing that exceeds the discounted cash flow estimate and a price‑to‑earnings multiple that dwarfs the industry average. The stock shows a bullish technical backdrop – the moving averages sit below the current price, MACD is in a bullish configuration and momentum indicators remain comfortably below overbought levels – yet the overall trend is described as neutral. Revenue growth remains robust, but margins are thin and operating profitability is marginal, contributing to a valuation gap. The dividend yield is modest, though cash flow generation and a moderate payout ratio suggest sustainability. Increased trading activity points to rising interest, but high recent volatility and a beta near market levels amplify risk considerations.
Given the juxtaposition of strong top‑line growth against elevated valuation and sector‑specific uncertainties, the stock may appeal to investors seeking exposure to defense technology but warrants careful positioning. The combination of a high price relative to fair value, substantial volatility, and a balanced dividend profile underlines the need for a nuanced, time‑horizon‑specific approach.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • bullish technical signals but neutral overall trend
  • price above intrinsic valuation
  • high short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • sustained revenue growth outpacing peers
  • potential for margin improvement
  • moderate dividend sustainability

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • defense sector cyclicality and regulatory exposure
  • valuation gap may persist without earnings acceleration
  • steady cash flow supporting dividend

Key Metrics & Analysis

Financial Health

Revenue Growth25.60%
Profit Margin3.91%
P/E Ratio85.9
ROE10.30%
ROA2.92%
Debt/Equity167.14
P/B Ratio10.7
Op. Cash Flow$498.0M
Free Cash Flow$265.5M
Industry P/E29.7

Technical Analysis

TrendNeutral
RSI64.5
Support$8.16
Resistance$10.46
MA 20$9.04
MA 50$9.03
MA 200$9.80
MACDBullish
VolumeIncreasing
Fear & Greed Index91.75

Valuation

Fair Value$7.45
GradeOvervalued
TypeGrowth
Dividend Yield0.62%

Risk Assessment

Beta1.02
Volatility58.24%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.